Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating / 대한소화기학회지
The Korean Journal of Gastroenterology
; : 121-127, 2018.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-717120
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Abdominal bloating is a troublesome complaint due to insufficient understanding of the pathophysiology. The aim of this study was to evaluate the efficacy of rifaximin in reducing bloating associated with functional gastrointestinal disorders (FGIDs).METHODS:
A total of 63 patients were treated with rifaximin for FGIDs with bloating or gas-related symptoms between 2007 and 2013 at Seoul National University Bundang Hospital. Rifaximin was administered at a dose between 800 mg/day and 1,200 mg/day for 5 to 14 days. The proportion of patients who had adequate relief of global FGID symptoms and FGID-related bloating was retrospectively assessed. The response was recorded when the symptoms were reduced by at least 50% at the follow-up after treatment cessation.RESULTS:
The mean age was 56.8±14.2 years; 49.2% were females. According to Rome III criteria, 20.6% (13/63) had irritable bowel syndrome (IBS) with constipation, 9.5% (6/63) had IBS with diarrhea, 4.8% (3/63) had mixed IBS, 23.8% (15/63) had functional dyspepsia, and 12.7% (8/63) had functional bloating. Of the 51 subjects who were followed-up, 30 (58.8%) had adequate relief of global FGID symptoms and 26 (51.0%) experienced improvement of abdominal bloating after rifaximin treatment. The proportion of female was slightly higher in non-response group than in the response group (60.0% vs. 34.6%, p=0.069). Otherwise, there was no difference between the two groups.CONCLUSIONS:
Despite the limitations of this retrospective study, our data confirms that rifaximin may be beneficial for abdominal bloating. Further prospective clinical trial with a larger cohort is needed.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
Neglected Diseases
Health problem:
Target 3.3: End transmission of communicable diseases
/
Diarrhea
/
Neglected Diseases
Database:
WPRIM (Western Pacific)
Main subject:
Prospective Studies
/
Retrospective Studies
/
Cohort Studies
/
Follow-Up Studies
/
Constipation
/
Withholding Treatment
/
Irritable Bowel Syndrome
/
Diarrhea
/
Dyspepsia
/
Seoul
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Female
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
The Korean Journal of Gastroenterology
Year:
2018
Document type:
Article